Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 11/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954924 | 1.00 | KCNA5 (0.56) | KCNA5PDE4DALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL15146071 | 0.98 | KCNA5 (0.55) | KCNA5PDE4DALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL6947507 | 0.98 | KCNA5 (0.55) | KCNA5PDE4DALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL6954054 | 0.98 | KCNA5 (0.55) | KCNA5PDE4DALDH1A1LMNAKDM4E | |
| Cadaverine Tartrate SCHEMBL27569553 | 0.92 | KCNA5 (0.51) | KCNA5PDE4DLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL1294805 | 0.85 | LMNA (0.43) | KCNA5PDE4DLMNAMEN1KMT2A | |
| SCHEMBL1294809 | 0.85 | LMNA (0.43) | KCNA5PDE4DLMNAMEN1KMT2A | |
| SCHEMBL7130315 | 0.85 | LMNA (0.43) | KCNA5PDE4DLMNAMEN1KMT2A | |
| SCHEMBL25564133 | 0.85 | KCNA5 (0.54) | KCNA5PDE4DLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL16178281 | 0.84 | LMNA (0.42) | KCNA5PDE4DLMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021147699-A1 | PYRIDOHETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
| CN-103906743-A | Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi | PIRAMAL IMAGING SA | 2014-07-02 | — | — | CN | disclosed |
| EP-1988078-B1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | ORTHO MCNEIL PHARM INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| US-20090149528-A1 | Cinnamic acid amides | BAYER HEALTHCARE AG (DE) | 2009-06-11 | — | — | US | disclosed |
| EP-1988078-A1 | Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders | Ortho-McNeil Pharmaceutical, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| US-7402683-B2 | 3-(1,3-benzodioxol-5-yl)-N-{(1S)-3-[((1S)-2-methyl-1-{[(3R,4S)-4-methyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}propyl)amino]-3-oxo-1-phenylpropyl}-2-propenamide; bactericide, bacterial infection; septic infections, bone and joint infections, skin infections; veterinary medicine | BAYER HEALTHCARE AG (DE) | 2008-07-22 | — | — | US | disclosed |
| US-7348357-B2 | bactericide; derivatives of pseudopeptide Andrimid in which beta-phenylalanine amide is replaced by heteroaromatic or substituted aromatic amide; N-{(1S)-3-[((1S)-1-{[(3R,4S)-1,4-Dimethyl-2,5-dioxo-3-pyrrolidinyl]carbonyl}-2-methylpropyl)amino]-3-oxo-1-phenylpropyl}-2-pyridinecarboxamide; antibiotics | BAYER HEALTHCARE AG (DE) | 2008-03-25 | — | — | US | disclosed |
| EP-1165543-A1 | PROCESS FOR PREPARING S-(R*,S*)] -$g(b) - 1- 1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| CN-1320125-A | Trizolopyridines for the treamtent of thrombosis disorders | ORTHO MCNEIL PHARM INC (US) | 2001-10-31 | — | — | CN | disclosed |
| CN-1286684-A | Carboxamide derivs. of pyrrolidine, piperidine and hexahydroazepine for treatment of thrombosis disorders | ORTHO PHARMA CORP (US) | 2001-03-07 | — | — | CN | disclosed |
| WO-2000056730-A1 | PROCESS FOR PREPARING [S-(R*,S*)] -β -[[[1-[1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| US-6069254-A | Carboxamide derivatives of piperidine for the treatment of thrombosis disorders | ORTHO PHARMACEUTICAL CORP. (US) | 2000-05-30 | — | — | US | disclosed |
| EP-0923555-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997041102-A1 | CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
| EP-0355819-B1 | Substituted aryl ureas as high potency sweeteners | NUTRASWEET CO (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1990002112-A1 | SUBSTITUTED ARYL UREAS AS HIGH POTENCY SWEETENERS | THE NUTRASWEET COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355819-A1 | Substituted aryl ureas as high potency sweeteners | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149528-A1 | Cinnamic acid amides | PIGS, NISCH, PIGO | KCNA5 1557/4885PDE4D 3461/4885ALDH1A1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.